BMS’ Opdivo HCC trial to start enrolling Phase II in January 2016 - investigator

11 Jun 2015

Bristol-Myers Squibb (NYSE:BMY) will start enrolling patients in January 2016 in the Phase II part of the Phase I/II Opdivo (nivolumab) trial in hepatocellular carcinoma (HCC), said an investigator. Speaking to this news service at the recent 2015 American Society of Clinical Oncology meeting, he noted the study will recruit approximately 200 patients.

1 Start 2 Complete